Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Todd Lyda is active.

Publication


Featured researches published by Todd Lyda.


PLOS Neglected Tropical Diseases | 2010

A target-based high throughput screen yields Trypanosoma brucei hexokinase small molecule inhibitors with antiparasitic activity

Elizabeth R. Sharlow; Todd Lyda; Heidi Dodson; Gabriela Mustata; Meredith Morris; Stephanie Leimgruber; Kuo Hsiung Lee; Yoshiki Kashiwada; David Close; John S. Lazo; James C. Morris

Background The parasitic protozoan Trypanosoma brucei utilizes glycolysis exclusively for ATP production during infection of the mammalian host. The first step in this metabolic pathway is mediated by hexokinase (TbHK), an enzyme essential to the parasite that transfers the γ-phospho of ATP to a hexose. Here we describe the identification and confirmation of novel small molecule inhibitors of bacterially expressed TbHK1, one of two TbHKs expressed by T. brucei, using a high throughput screening assay. Methodology/Principal Findings Exploiting optimized high throughput screening assay procedures, we interrogated 220,233 unique compounds and identified 239 active compounds from which ten small molecules were further characterized. Computation chemical cluster analyses indicated that six compounds were structurally related while the remaining four compounds were classified as unrelated or singletons. All ten compounds were ∼20-17,000-fold more potent than lonidamine, a previously identified TbHK1 inhibitor. Seven compounds inhibited T. brucei blood stage form parasite growth (0.03≤EC50<3 µM) with parasite specificity of the compounds being demonstrated using insect stage T. brucei parasites, Leishmania promastigotes, and mammalian cell lines. Analysis of two structurally related compounds, ebselen and SID 17387000, revealed that both were mixed inhibitors of TbHK1 with respect to ATP. Additionally, both compounds inhibited parasite lysate-derived HK activity. None of the compounds displayed structural similarity to known hexokinase inhibitors or human African trypanosomiasis therapeutics. Conclusions/Significance The novel chemotypes identified here could represent leads for future therapeutic development against the African trypanosome.


Experimental Parasitology | 2011

Quercetin, a fluorescent bioflavanoid, inhibits Trypanosoma brucei hexokinase 1

Heidi Dodson; Todd Lyda; Jeremy W. Chambers; Meredith Morris; Kenneth A. Christensen; James C. Morris

Hexokinases from the African trypanosome, Trypanosoma brucei, are attractive targets for the development of anti-parasitic drugs, in part because the parasite utilizes glycolysis exclusively for ATP production during the mammalian infection. Here, we have demonstrated that the bioflavanoid quercetin (QCN), a known trypanocide, is a mixed inhibitor of Trypanosoma brucei hexokinase 1 (TbHK1) (IC(50) = 4.1 ± 0.8μM). Spectroscopic analysis of QCN binding to TbHK1, taking advantage of the intrinsically fluorescent single tryptophan (Trp177) in TbHK1, revealed that QCN quenches emission of Trp177, which is located near the hinge region of the enzyme. ATP similarly quenched Trp177 emission, while glucose had no impact on fluorescence. Supporting the possibility that QCN toxicity is a consequence of inhibition of the essential hexokinase, in live parasites QCN fluorescence localizes to glycosomes, the subcellular home of TbHK1. Additionally, RNAi-mediated silencing of TbHK1 expression expedited QCN induced death, while over-expressing TbHK1 protected trypanosomes from the compound. In summary, these observations support the suggestion that QCN toxicity is in part attributable to inhibition of the essential TbHK1.


Experimental Parasitology | 2009

Trypanosoma brucei AMP-activated kinase subunit homologs influence surface molecule expression

Clarice S. Clemmens; Meredith Morris; Todd Lyda; Alvaro Acosta-Serrano; James C. Morris

The African trypanosome, Trypanosoma brucei, can gauge its environment by sensing nutrient availability. For example, procyclic form (PF) trypanosomes monitor changes in glucose levels to regulate surface molecule expression, which is important for survival in the tsetse fly vector. The molecular connection between glycolysis and surface molecule expression is unknown. Here we partially characterize T. brucei homologs of the beta and gamma subunits of the AMP-activated protein kinase (AMPK), and determine their roles in regulating surface molecule expression. Using flow cytometry and mass spectrometry, we found that TbAMPKbeta or TbAMPKgamma-deficient parasites express both of the major surface molecules, EP- and GPEET-procyclin, with the latter being a form that is expressed when glucose is low such as in the tsetse fly. Last, we have found that the putative scaffold component of the complex, TbAMPKbeta, fractionates with organellar components and colocalizes in part with a glycosomal marker as well as the flagellum of PF parasites.


Molecular and Cellular Biochemistry | 2015

A unique, highly conserved secretory invertase is differentially expressed by promastigote developmental forms of all species of the human pathogen, Leishmania

Todd Lyda; Manju B. Joshi; John F. Andersen; Andrew Y. Kelada; Joshua P. Owings; Paul A. Bates; Dennis M. Dwyer


Archive | 2011

Identification of Inhibitors of Trypanosoma brucei Hexokinases

Elizabeth R. Sharlow; Jennifer E. Golden; Heidi Dodson; Meredith Morris; Marcia Hesser; Todd Lyda; Stephanie Leimgruber; Chad E. Schroeder; Daniel P. Flaherty; Warren S. Weiner; Denise S. Simpson; John S. Lazo; Jeffrey Aubé; James C. Morris


Archive | 2011

Small Molecule Inhibitors of Trypanosoma brucei Hexokinase 1

Daniel P. Flaherty; Chad E. Schroeder; Denise S. Simpson; Elizabeth R. Sharlow; Jennifer E. Golden; Heidi Dodson; Meredith Morris; Marcia Hesser; Todd Lyda; Stephanie Leimgruber; Warren S. Weiner; John S. Lazo; Jeffrey Aubé


Archive | 2011

Table 2, SAR summary for compounds with carboxylic acid isosteric replacements

Elizabeth R. Sharlow; Jennifer E. Golden; Heidi Dodson; Meredith Morris; Marcia Hesser; Todd Lyda; Stephanie Leimgruber; Chad E. Schroeder; Dan P Flaherty; Warren S. Weiner; Denise S. Simpson; John S. Lazo; Jeffrey Aubé; James C Morris


Archive | 2011

Table 7, Comparison of quercetin and probe

Elizabeth R. Sharlow; Jennifer E. Golden; Heidi Dodson; Meredith Morris; Marcia Hesser; Todd Lyda; Stephanie Leimgruber; Chad E. Schroeder; Dan P Flaherty; Warren S. Weiner; Denise S. Simpson; John S. Lazo; Jeffrey Aubé; James C Morris


Archive | 2011

[Table], User Chromatogram Peak List

Elizabeth R. Sharlow; Jennifer E. Golden; Heidi Dodson; Meredith Morris; Marcia Hesser; Todd Lyda; Stephanie Leimgruber; Chad E. Schroeder; Dan P Flaherty; Warren S. Weiner; Denise S. Simpson; John S. Lazo; Jeffrey Aubé; James C Morris


Archive | 2011

Figure 14, [A. probe structure; B. dose...].

Elizabeth R. Sharlow; Jennifer E. Golden; Heidi Dodson; Meredith Morris; Marcia Hesser; Todd Lyda; Stephanie Leimgruber; Chad E. Schroeder; Dan P Flaherty; Warren S. Weiner; Denise S. Simpson; John S. Lazo; Jeffrey Aubé; James C Morris

Collaboration


Dive into the Todd Lyda's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge